Insulin receptor antibody-iduronate 2-sulfatase fusion protein: Pharmacokinetics, anti-drug antibody, and safety pharmacology in Rhesus monkeys

Biotechnology and Bioengineering

Volumn 111, Issue 11, 2014, Pages 2317-2325

  Boado, Ruben J ^a   Ka Wai Hui, Eric ^a   Zhiqiang Lu, Jeff ^a   Pardridge, William M ^a  

^a ArmaGen Technologies Inc   (United States)

Author keywords

Blood brain barrier; Drug delivery; Lysosomal enzyme; Monoclonal antibody

Indexed keywords

ANTIBODIES; BIOCHEMISTRY; BLOOD; DRUG DELIVERY; DRUG THERAPY; ENZYME ACTIVITY; ENZYMES; GENE ENCODING; INSULIN; MAMMALS; MONOCLONAL ANTIBODIES; PHARMACOKINETICS; SECURITY OF DATA;

BLOOD-BRAIN BARRIER; CLINICAL CHEMISTRY; ENZYME REPLACEMENT THERAPY; LYSOSOMAL ENZYMES; MONOCLONAL ANTIBODIES (MAB); PLASMA CONCENTRATION; RECEPTOR-MEDIATED TRANSPORTS; SAFETY PHARMACOLOGY;

PROTEINS;

DRUG ANTIBODY; HYBRID PROTEIN; IDURONATE 2 SULFATASE; INSULIN RECEPTOR ANTIBODY; GLYCOPROTEIN; IDS PROTEIN, HUMAN; INSR PROTEIN, HUMAN; INSULIN RECEPTOR; LEUKOCYTE ANTIGEN; MONOCLONAL ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; BIOTINYLATION; BLOOD BRAIN BARRIER; BRAIN; CEREBELLUM; CHO CELL LINE; CHRONIC DRUG ADMINISTRATION; CONTROLLED STUDY; CROSS REACTION; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG MEGADOSE; DRUG SAFETY; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENETIC TRANSFECTION; HISTOPATHOLOGY; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; IN VITRO STUDY; IN VIVO STUDY; LONG TERM CARE; LOW DRUG DOSE; MALE; MAXIMUM PLASMA CONCENTRATION; MEAN RESIDENCE TIME; NONHUMAN; PHARMACODYNAMICS; PLASMA CLEARANCE; RHESUS MONKEY; SPINAL CORD; ANIMAL; CHEMISTRY; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; GENETICS; IMMUNOLOGY; INTRAVENOUS DRUG ADMINISTRATION; METABOLIC CLEARANCE RATE; PATHOLOGY; PLASMA;

EQUIDAE; MACACA MULATTA;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; GLYCOPROTEINS; INFUSIONS, INTRAVENOUS; MACACA MULATTA; METABOLIC CLEARANCE RATE; PLASMA; RECEPTOR, INSULIN; RECOMBINANT FUSION PROTEINS;

EID: 84925258031     PISSN: 00063592     EISSN: 10970290     Source Type: Journal    
DOI: 10.1002/bit.25289     Document Type: Article

References (22)

1. Al Sawaf S, Mayatepek E, Hoffmann B. 2008. Neurological findings in Hunter disease: Pathology and possible therapeutic effects reviewed. J Inherit Metab Dis 31:473-480.
2. Boado RJ, Hui EK-W, Lu JZ, Pardridge WM. 2009. AGT-181: Expression in CHO cells and pharmacokinetics, safety, and plasma iduronidase enzyme activity in Rhesus monkeys. J Biotechnol 144:135-141.
3. Boado RJ, Hui EK-W, Lu JZ, Pardridge WM. 2012. Glycemic control and chronic dosing of Rhesus monkeys with a fusion protein of iduronidase and a monoclonal antibody against the human insulin receptor. Drug Metab Dispos 40:2021-2025.
4. Boado RJ, Hui EK-W, Lu JZ, Pardridge WM. 2013b. IgG-enzyme fusion potein: Pharmacokinetics and anti-drug antibody response in Rhesus monkeys. Bioconj Chem 24:97-104.
5. Boado RJ, Hui EK-W, Lu JZ, Sumbria RK, Pardridge WM. 2013a. Blood-brain barrier molecular trojan horse enables brain imaging of radioiodinated recombinant protein in the Rhesus monkey. Bioconj Chem 24:1741-1749.
6. Couch JA, Yu YJ, Zhang Y, Tarrant JM, Fuji RN, Meilandt WJ, Solanoy H, Tong RK, Hoyte K, Luk W, Lu Y, Gadkar K, Prabhu S, Ordonia BA, Nguyen Q, Lin Y, Lin Z, Balazs M, Scearce-Levie K, Ernst JA, Dennis MS, Watts RJ. 2013. Addressing safety liabilities of TfR bispecific antibodies that cross the blood-brain barrier. Sci Transl Med 5:183ra157, 1-12.
7. Duffy KR, Pardridge WM. 1987. Blood-brain barrier transcytosis of insulin in developing rabbits. Brain Res 420:32-38.
8. Felice BR, Wright TL, Boyd RB, Butt MT, Pfeifer RW, Pan J, Ruiz JA, Heartlein MW, Calias P. 2011. Safety evaluation of chronic intrathecal administration of idursulfase-IT in cynomolgus monkeys. Toxicol Pathol 39:879-892.
9. Garman RH. 2003. Evaluation of large-sized brains for neurotoxic endpoints. Toxicol Pathol 31 Suppl:32-43.
10. Lu JZ, Boado RJ, Hui EK-H, Zhou Q-H, Pardridge WM. 2011. Expression in CHO cells and pharmacokinetics and brain uptake in the Rhesus monkey of an IgG-iduronate-2-sulfatase fusion protein. Biotechnol Bioeng 108:1954-1964.
11. Lu JZ, Hui EK-W, Boado RJ, Pardridge WM. 2010. Genetic engineering of a bifunctional IgG fusion protein with iduronate-2-sulfatase. Bioconj Chem 21:151-156.
12. Muenzer J, Wraith JE, Beck M, Giugliani R, Harmatz P, Eng CM, Vellodi Martin AR, Ramaswami U, Gucsavas-Calikoglu M, Vijayaraghavan S, Wendt S, Puga AC, Ulbrich B, Shinawi M, Cleary M, Piper D, Conway AM, Kimura A. 2006. A phase II/III clinical study of enzyme replacement therapy with idursulfase in mucopolysaccharidosis II (Hunter syndrome). Genet Med 8:465-473.
13. Pardridge WM, Boado RJ. 2009. Pharmacokinetics and safety in Rhesus monkeys of a monoclonal antibody-GDNF fusion protein for targeted blood-brain barrier delivery. Pharm Res 26:2227-2236.
14. Pardridge WM, Boado RJ. 2012. Reengineering biopharmaceuticals for targeted delivery across the blood-brain barrier. Methods Enzymol. 503:269-292.
15. Pardridge WM, Eisenberg J, Yang J. 1985. Human blood-brain barrier insulin receptor. J Neurochem 44:1771-1778.
16. Pardridge WM, Kang YS, Buciak JL, Yang J. 1995. Human insulin receptor monoclonal antibody undergoes high affinity binding to human brain capillaries in vitro and rapid transcytosis through the blood-brain barrier in vivo in the primate. Pharm Res 12:807-816.
17. Scarpa M. 2013. Evaluation of idursulfase for the treatment of mucopolysaccharidosis II (Hunter syndrome). Expert Opin Orphan Drugs 1:89-98.
18. Voznyi YV, Keulemans JL, van Diggelen OP. 2001. A fluorimetric enzyme assay for the diagnosis of MPS II (Hunter disease). J Inherit Metab Dis 24:675-680.
19. Wilson PJ, Morris CP, Anson DS, Occhiodoro T, Bielicki J, Clements PR, Hopwood JJ. 1990. Hunter syndrome: Isolation of an iduronate-2-sulfatase cDNA clone and analysis of patient DNA. Proc Natl Acad Sci USA 87:8531-8535.
20. Wraith JE, Scarpa M, Beck M, Bodamer OA, De Meirleir L, Guffon L, Meldgaard Lund A, Malm G, Van der Ploeg AT, Zeman J. 2008. Mucopolysaccharidosis type II (Hunter syndrome): A clinical review and recommendations for treatment in the era of enzyme replacement therapy. Eur J Pediatr 167:267-277.
21. Zhou Q-H, Boado RJ, Lu JZ, Hui EK-W, Pardridge WM. 2011. Chronic dosing of mice with a transferrin receptor monoclonal antibody-GDNF fusion protein. Drug Metab Dispos 39:1149-1154.
22. Zhou QH, Boado RJ, Pardridge WM. 2012. Selective plasma pharmacokinetics and brain uptake in the mouse of enzyme fusion proteins derived from species-specific receptor-targeted antibodies. J Drug Target 20:715-719.